Interestingly, ferroportin overexpression can cause cell cycle arrest, and suppress tumour occurrence and growth [69], thereby showcasing the therapeutic potential of targeting the hepcidin–ferroportin axis in cancers. The gene discussed is SLC40A1; the disease is cancer.